Company intelligence / Profile preview

Biocytogen

Ownership: Public · 02315
Development stage: Other

Overview

Biocytogen has developed a pipeline of at least ten core antibody assets. Lead programs such as YH001 (anti–CTLA–4) and YH002 (anti–OX40) have shown favorable safety/efficacy profiles in Phase I trials. The company’s proprietary platforms enable rapid generation of fully human antibodies against a wide range of targets. Multiple candidates are being evaluated alone or in combination therapies for solid tumors.

Therapeutic areas: OncologyImmunology
Modalities: Monoclonal antibodies (mAbs)Bispecific/multispecific antibodiesNanobodiesAntibody-drug conjugates (ADCs)
Industry: Biotech

Drug pipeline

55 assets

YH002

54 more assets in the full pipeline.

Partnerships

SOTIO BiotechOna TherapeuticsAcepodiamultiple multinational pharmaceutical companies (>50 co-development/outlicensing agreements globally)

Financials

Market cap: $2.4B
Total revenue: $206.7M
Enterprise value: $2.3B

Beyond the preview

Go deeper on Biocytogen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biocytogen.